Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin - PubMed (original) (raw)
. 2000 Nov 17;275(46):35778-85.
doi: 10.1074/jbc.M004267200.
Affiliations
- PMID: 10958792
- DOI: 10.1074/jbc.M004267200
Free article
Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin
D L Persons et al. J Biol Chem. 2000.
Free article
Abstract
The p53 tumor suppressor protein is a transcription factor that plays a major role in the DNA damage response. After DNA damage, p53 levels increase due primarily to stabilization of the protein. The molecular mechanisms leading to stabilization of p53 after DNA damage have not been completely elucidated. Recently we reported that cisplatin treatment activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and that inhibition of ERK1/2 resulted in enhanced sensitivity to cisplatin. In the present study, we examined the potential role of ERK1/2 activation in regulation of the p53 response to cisplatin. In the ovarian carcinoma cell line A2780, inhibition of ERK1/2 activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53 protein during exposure to cisplatin. We also demonstrated that p53 protein co-immunoprecipitated with ERK1/2 protein and was phosphorylated by activated recombinant murine ERK2 in vitro. Furthermore, PD98059 decreased the phosphorylation of p53 at serine 15 during cisplatin exposure, suggesting that ERK1/2 mediates in part phosphorylation of p53 during the cisplatin DNA response. These results strongly suggest that cisplatin-induced ERK activation is an up-stream regulator of the p53 response to DNA damage caused by cisplatin.
Similar articles
- Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
DeHaan RD, Yazlovitskaya EM, Persons DL. DeHaan RD, et al. Cancer Chemother Pharmacol. 2001 Nov;48(5):383-8. doi: 10.1007/s002800100318. Cancer Chemother Pharmacol. 2001. PMID: 11761456 - Cisplatinum and taxol induce different patterns of p53 phosphorylation.
Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M, Broggini M. Damia G, et al. Neoplasia. 2001 Jan-Feb;3(1):10-6. doi: 10.1038/sj.neo.7900122. Neoplasia. 2001. PMID: 11326311 Free PMC article. - Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH. Mujoo K, et al. J Cancer Res Clin Oncol. 2003 Dec;129(12):709-18. doi: 10.1007/s00432-003-0480-4. Epub 2003 Sep 26. J Cancer Res Clin Oncol. 2003. PMID: 14513366 - Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y. Hayakawa J, et al. Cancer Res. 2000 Nov 1;60(21):5988-94. Cancer Res. 2000. PMID: 11085518 - Regulation and pathological role of p53 in cisplatin nephrotoxicity.
Jiang M, Dong Z. Jiang M, et al. J Pharmacol Exp Ther. 2008 Nov;327(2):300-7. doi: 10.1124/jpet.108.139162. Epub 2008 Aug 5. J Pharmacol Exp Ther. 2008. PMID: 18682572 Review.
Cited by
- A better experimental method to detect the sensitivity of cancer cells to anticancer drugs after adenovirus-mediated introduction of two kinds of p53 in vivo.
Wang H, Li W, Lai B, Yang X, Zhang C, Li J, Zhu Y. Wang H, et al. Anticancer Drugs. 2015 Sep;26(8):852-9. doi: 10.1097/CAD.0000000000000259. Anticancer Drugs. 2015. PMID: 26164152 Free PMC article. - A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells.
Muscella A, Vetrugno C, Fanizzi FP, Manca C, De Pascali SA, Marsigliante S. Muscella A, et al. Cell Death Dis. 2013 Sep 12;4(9):e796. doi: 10.1038/cddis.2013.315. Cell Death Dis. 2013. PMID: 24030148 Free PMC article. - Effects of heavy metals on mitogen-activated protein kinase pathways.
Matsuoka M, Igisu H. Matsuoka M, et al. Environ Health Prev Med. 2002 Jan;6(4):210-7. doi: 10.1007/BF02897972. Environ Health Prev Med. 2002. PMID: 21432337 Free PMC article. - Neuroprotective Effects of Neuropeptide Y on Human Neuroblastoma SH-SY5Y Cells in Glutamate Excitotoxicity and ER Stress Conditions.
Palanivel V, Gupta V, Mirshahvaladi SSO, Sharma S, Gupta V, Chitranshi N, Mirzaei M, Graham SL, Basavarajappa D. Palanivel V, et al. Cells. 2022 Nov 18;11(22):3665. doi: 10.3390/cells11223665. Cells. 2022. PMID: 36429093 Free PMC article. - Cell proliferation, apoptosis and mitochondrial damage in rat B50 neuronal cells after cisplatin treatment.
Bottone MG, Soldani C, Veneroni P, Avella D, Pisu M, Bernocchi G. Bottone MG, et al. Cell Prolif. 2008 Jun;41(3):506-20. doi: 10.1111/j.1365-2184.2008.00530.x. Epub 2008 Apr 7. Cell Prolif. 2008. PMID: 18397337 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous